Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study checks Tivozanib's performance in kidney cancer

NCT ID NCT07354282

Knowledge-focused Sponsor: Spanish Oncology Genito-Urinary Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked back at the medical records of 200 patients with advanced clear cell kidney cancer who received Tivozanib as their first treatment. The goal was to see how long patients went without their cancer getting worse and how long they lived overall. The study focused on patients considered to have a favorable outlook based on a standard risk score.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tivozanib
What this could lead to
If results are positive, this could confirm that Tivozanib is a good first-line option for certain patients with advanced kidney cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only looks back at past data and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

May 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The population of this study consists of patients diagnosed with metastatic renal cell carcinoma (mRCC) who initiated first-line treatment with Tivozanib between March 1, 2019, and August 31, 2024.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \- Patients ≥ 18 years old. 2. \- Who have signed the informed consent form, except for patients who were deceased at the time of inclusion. 3. \- Histological diagnosis of stage IV clear cell renal carcinoma. 4. \- Who started treatment with Tivozanib as first-line therapy between March 1, 2019, and August 31, 2024. 5. \- Who received treatment at the participating center. Exclusion Criteria: 1. \- Patients previously treated at another center who were later referred to one of the participating centers. In this case, the patient will be included in the center where the treatment was initiated. 2. \- Explicit objection by the subject or their legal representative to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic clear cell renal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal cell cancer metastatic

Contacts and locations

Locations

  • Fundacion Jimenez Diaz

    Madrid, Madrid, Spain

  • Hospital Gregorio Marañon

    Madrid, Madrid, Spain

  • Hospital Lucus Augusti

    Lugo, Galicia, Spain

  • Hospital Parc Tauli

    Sabadell, Catalonia, Spain

  • Hospital Puerta de Hierro

    Majadahonda, Madrid, Spain

  • Hospital Reina Sofia

    Córdoba, Andalusia, Spain

  • Hospital Severo Ochoa

    Leganés, Madrid, Spain

  • Hospital Vall de Hebron

    Barcelona, Catalonia, Spain

  • Hospital Virgen de la Victoria

    Málaga, Andalusia, Spain

  • Hospital Virgen del Rocio

    Seville, Andalusia, Spain

  • Hospital de Burgos

    Burgos, Castille and León, Spain

  • Hospital de Leon

    León, Castille and León, Spain

  • Institut Català d'Oncologia (ICO) de L'Hospitalet de Llobregat

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Instituto Valenciano de Oncologia (IVO)

    Valencia, Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.